Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation

Akatsuki Saito, Takashi Irie, Rigel Suzuki, +53

Nature

Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus

Hirotaka Ebina, Naoko Misawa, Yuka Kanemura, +1

Scientific Reports

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants

Tomokazu Tamura, Jumpei Ito, Keiya Uriu, +82

Nature Communications

Cell-to-cell infection by HIV contributes over half of virus infection

Shingo Iwami, Junko S. Takeuchi, Shinji Nakaoka, +8

eLife

Hiv-1 SpreadVirus InfectionHuman RetrovirusPathogenesisImmunology +10

Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant

Jumpei Ito, Rigel Suzuki, Keiya Uriu, +78

Nature Communications

Various Omicron SubvariantsGeneticsViral PathogenesisGenomicsPhylogenetic Analysis +19

Critical Contribution of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) to Apoptosis of Human Cd4+T Cells in HIV-1–Infected Hu-Pbl-Nod-Scid Mice

Yoshiharu Miura, Naoko Misawa, Naoyoshi Maeda, +8

The Journal of Experimental Medicine

Modulation of Human Immunodeficiency Virus Type 1 Infectivity through Incorporation of Tetraspanin Proteins

Kei Sato, Jun Aoki, Naoko Misawa, +4

Journal of Virology

HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication

T Izumi, Katsuhiro Io, Masashi Matsui, +10

Proceedings of the National Academy of Sciences

Viral ReplicationHuman RetrovirusImmunologyViral Infectivity FactorMolecular Biology +7

A novel animal model of Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis in humanized mice

Kei Sato, Naoko Misawa, Chuanyi Nie, +8

Blood

Primary human immunodeficiency virus type 1 viremia and central nervous system invasion in a novel hu-PBL-immunodeficient mouse strain

Yoshio Koyanagi, Yuetsu Tanaka, Jun‐ichi Kira, +14

Journal of Virology

Hu-pbl-scid MiceViral PathogenesisImmunologyPathologyImmunotherapy +16